LublinFDReingoldSCCohenJA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology2014; 83(3): 278–286.
2.
MahadDHTrappBDLassmannH.Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol2015; 14(2): 183–193.
3.
ZiemssenTDerfussTde StefanoN, et al. Optimizing treatment success in multiple sclerosis. J Neurol2016; 263(6): 1053–1065.
4.
GoodinDSTraboulseeAKnappertzV, et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry2012; 83(3): 282–287.
5.
Meyer-MoockSFengYSMaeurerM, et al. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol2014; 14: 58.
6.
CohenJACutterGRFischerJS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology2002; 59(5): 679–687.
7.
HawkerKO’ConnorPFreedmanMS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol2009; 66(4): 460–471.
8.
GoodkinDERudickRAVanderBrug MedendorpS, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol1995; 37(1): 30–40.
9.
SipeJCRomineJSKoziolJA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet1994; 344(8914): 9–13.
10.
GiovannoniGCutterGPia-SormaniM, et al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Mult Scler Relat Disord2017; 12: 70–78.
11.
CadavidDCohenJAFreedmanMS, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler2017; 23(1): 94–105.
12.
KremenchutzkyMRiceGPABaskervilleJ, et al. The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease. Brain2006; 129(Pt 3): 584–594.
13.
FeysPGiovannoniGDijsselbloemN, et al. The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Mult Scler2016; 22(2 Suppl.): 34–46.
14.
DubuissonNBauerABuckleyM, et al. Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. Mult Scler Relat Disord2017; 17: 172–176.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
